Author

P. Bieniasz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Organism:human· 1 Organism:non-human primate· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Muecksch· 3 shared T. Hatziioannou· 3 shared A. Cho· 2 shared A. Gazumyan· 2 shared C. Barnes· 2 shared C. Gaebler· 2 shared F. Schmidt· 2 shared K. Huey-Tubman· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Muecksch

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.

G. Baisa, D. Rancour, K. Mansfield, M. Burns, L. Martin, D. Cunha, J. Fischer, F. Muecksch, T. Hatziioannou, P. Bieniasz, F. Schomburg, K. Luke

This study evaluates a recombinant SARS-CoV-2 vaccine in macaques, showing that antigens from the RBD elicit high-titer neutralizing antibodies lasting over 20 weeks.

bioRxiv · Dec 20, 2020 · PreprintImmunology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology